CTMX CytomX Therapeutics Forecast, Technical & Fundamental Analysis
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment... Show more
CTMX is expected to report earnings to fall 18.20% to -8 cents per share on August 06
Q2'26
Est.
$-0.08
Q1'26
Beat
by $0.02
Q4'25
Missed
by $0.08
Q3'25
Missed
by $0.04
Q2'25
Beat
by $0.06
The last earnings report on May 07 showed earnings per share of -10 cents, beating the estimate of -11 cents. With 28.89M shares outstanding, the current market capitalization sits at 831.63M.
A.I. Advisor
published General Information
General Information
an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer
A.I.dvisor indicates that over the last year, CTMX has been loosely correlated with MLEC. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CTMX jumps, then MLEC could also see price increases.
Momentum Indicator for CTMX turns positive, indicating new upward trend
CTMX saw its Momentum Indicator move above the 0 level on June 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CTMX's RSI Oscillator exited the oversold zone, of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CTMX just turned positive on June 17, 2026. Looking at past instances where CTMX's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CTMX advanced for three days, in of 240 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for CTMX moved below the 200-day moving average on June 10, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTMX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CTMX broke above its upper Bollinger Band on June 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CTMX entered a downward trend on June 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CTMX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.069) is normal, around the industry mean (20.977). P/E Ratio (18.167) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). CTMX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (13.717) is also within normal values, averaging (367.979).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
